Submissions

Herein, CHPA provides comments on Citizen Petition FDA-2017-P-27331 which requests the addition of a warning to labeling for all OTC drug products labeled to relieve or prevent heartburn associated with reflux disease, acid indigestion, and sour stomach noting that these products do not eliminate the risk of esophageal cancer.

Herein CHPA provides comments on several questions from the U.S. Department of Agriculture’s Agricultural Marketing Service regarding the establishment of a National Bioengineered Food Disclosure Standard.

CHPA appreciates the opportunity to provide our comments to the EPA regarding the Executive order, "Enforcing the Regulatory Reform Agenda".

CHPA appreciates this opportunity to provide comments on FDA Guidance detailing the agency’s process for evaluating data on the beneficial physiological effects of isolated or synthetic non-digestible carbohydrates.

CHPA believes that FDA’s revised 2016 Draft Guidance is an important step in helping to improve manufacturer understanding of, and compliance with, the new dietary ingredient notification requirement in Section 413 of the Federal Food, Drug, and Cosmetic Act.

CHPA submits the following comments to the U.S. Office of Budget and Management (OMB) in response to a request for public input on a draft memorandum titled “Information Technology Modernization Initiative.”

CHPA appreciates the opportunity to provide comments on this matter. While none of our dietary supplement member companies currently market products containing vinpocetine, we have an interest in the subject matter and wish to provide our comments.

These comments are directed broadly towards three of the four goals identified by ODS.

Letter to Drs. Femia and Santos regarding multiple active ingredient product monographs.

Our member companies generally support the recommendations found in the guidance but have concerns about the scope of hardness measurements and maximum break strength value.